20 articles
Real-world study of 664 patients reveals effective treatment options after T-DXd discontinuation, with low lung disease recurrence rates.
A phase II trial explores whether the amino acid L-arginine, with or without enzyme inhibitors, can improve erectile function and quality of life after prostate cancer radiation therapy.
A randomized trial shows hormone receptor-positive/HER2+ early breast cancer patients had 100% 5-year overall survival with endocrine therapy plus dual HER2 blockade.
A 10-week supervised strength program targets chronic inflammation and self-efficacy in long-term allogeneic HCT survivors.
HIIT training studied in 52 men with prostate cancer on active surveillance to evaluate exercise benefits during watchful waiting.
ASTER 70s trial compares treatment intensities for women 70+ with genomically high-risk breast cancer to optimize outcomes while minimizing toxicity.
Japanese trial shows dual HER2 blockade with pertuzumab plus trastuzumab improves overall survival even after prior pertuzumab treatment.
The BEGONIA trial finds durvalumab combined with trastuzumab deruxtecan achieves 62% response rate in hard-to-treat metastatic breast cancer.
Innovative treatment combining three powerful drugs achieved 85% progression-free survival at one year in high-risk patients.
Small trial tests novel three-drug approach combining immune checkpoint inhibitor, vaccine, and inflammation blocker for metastatic cancers.
First study tests whether supervised exercise training is safe and beneficial for bladder cancer patients during treatment.
A completed pilot trial tested physical therapy and progressive muscle relaxation to preserve function and mood in older adults with advanced lung cancer.
Phase 1 data from 15 heavily pretreated Japanese myeloma patients confirms talquetamab's safety and efficacy, matching global trial results.
A phase 1 trial shows Temferon โ a gene-engineered stem cell therapy โ safely delivers interferon-ฮฑ into glioblastoma tumors with no dose-limiting toxicities.
New study shows circulating tumor cells can predict treatment response and reveal drug resistance patterns.
Small trial tests modified immune cells injected directly into chest cavity to fight aggressive cancer with 12-month survival rate.
Engineered immune cells target CD19+ cancer cells in patients with treatment-resistant lymphoma and leukemia.
Tucatinib-based treatment extends survival from 4.4 to 10 months for women with breast cancer that spread to brain lining.
A Phase 2 trial testing AR blockade combined with PD-1 inhibition in treatment-emergent neuroendocrine prostate cancer was terminated early.
Early PSMA upregulation after enzalutamide predicts shorter survival, but adding Lu-177-PSMA-617 improves outcomes in resistant prostate cancer.
